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ABSTRACT 
Objective:  To find out frequency of improvement in muscular rigidity after Pallidotomy in Parkinsonian patients 
who are medically refractory. 
Material and Methods:  This prospective descriptive study conducted in Neurosurgical Unit II, Punjab Institute 
of Neuro-Sciences, LGH, Lahore, during the period of one year from March 2015 to February 2016. They were 
evaluated before admission by history and thorough examination and then investigated with a CT scan and MRI 
of the brain. This study included patients as young as 30 years to as old as 65 years. Those patients who had 
trauma, stroke, demyelination or lesion in basal ganglia were excluded from the study. 
Result:  75 patients were included in the study with no lost to follow up. At the time of presentation, baseline 
rigidity graded as 3 in 37 (49.3%) and grade 4 in 38 (50.67%) patients. Reduction in rigidity at ≥ 25%, was 
considered significant improvement. At 3 months follow up 49 (65.3%) patients had UPRDS grade 1 while 26 
(34.7%) had (Unipied Parkinson’s Disease Rating Score) UPRDSS grade 2 and no patient shown UPRDS grade 
3 or 4. Out of 37 patients who had UPRDS grade 3 at baseline, 32 had grade 1 while 5 had grade 2 after 
Pallidotomy. Out of 38 patients, who had UPRDS grade 4 at baseline, 17 had UPRDS grade 1 while 21 had 
UPRDS grade 2 after pallidotomy. The difference was calculated to be significantly high (p < 0.001). 
Conclusion:  Pallidotomy is one of the successful surgical procedures to reduce Parkinsonian muscular rigidity. 
Keywords:  Parkinson’s disease, dyskinesia, rigidity, medically refractory, UPDRS (Urified Paskinsons Disease 
Rating Score). 
 
INTRODUCTION 
Parkinson’s disease (PD), after the name of English 
surgeon, James Parkinson, is a progressive and 
degenerative disease of dopamine producing neurons 
in different areas of the brain.
1
 It is characterized by 
bradykinesia, muscular rigidity, tremors, gait and 
postural instability. Its motor component becomes 
prominent when more than 50% loss of dopamine 
producing neurons occurred in Substantia nigra. This 
neuronal loss resulted in decreased amount of 
dopamine, the neurostimulator.
2
 
 The incidence of PD is different globally because 
of different factors like structural difference in 
population, the patient’s survival in a population, case 
ascertainment, data collection and methodology used 
to define the patient’s disease.3 It affects 1% of the 
population older than 60 years. Incidence of PD in 
different population is 11.4 to 15.5 cases per 100,000 
populations per year and age-adjusted incidence rate 
7.2 to 15.3 per 100,000 persons per year. 
4
 It not only 
involves motor system of the body, but non motor 
systems like autonomic dysfunction, neuropsychiatric 
disorders, thoughts changes, cognition, mood 
disorders, sensory and sleep problems also involve.
5
 
There is no definite etiology which resulting in 
Parkinson’s disease but some factors have a definite 
association in the pathophysiology of PD. These 
factors are patient’s genetics, environment (living in 
rural areas, consume well water), aging, chemical 
exposure (especially to herbicides and pesticides) and 
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lifestyle.
6
 Exposure to pesticides can increase the risk 
as much as 80%, which is subjective to period of 
exposure.
7
 
 This study was done to observe the effects of 
pallidotomy on Parkinsonian rigidity in whom the 
medical therapy causes adverse effects like dyskinesia 
by using Unified Parkinson’s Disease Rating Score 
Part 22 (rigidity component). This will help us to 
calculate statistical data for this surgical procedure in 
our region as there is no related study available 
previously and also observes the beneficial effects and 
related risks and complications. 
 
MATERIALS AND MEDTHODS 
Study Design 
This study was conducted in Neurosurgical Unit II, 
Punjab Institute of Neurosciences, Lahore General 
Hospital, Lahore, during the period of one year from 
March 2015 to February 2016. 
 
Inclusion Criteria 
There were 75 patients enrolled in this study, including 
both genders. Patients who are refractory to medicines 
(Levodopa and Carbidopa), who are 30 to 65 years old 
and who have muscular rigidity of grade 2 to 4 
included this study. 
 
Exclusion Criteria 
Those patients who have muscular rigidity due to 
stroke or infarction, demyelination, trauma or lesion in 
the basal ganglia were excluded from the study. 
 
Data Collection Procedure 
Seventy five patients admitted via outpatient 
department in Neurosurgery Unit II fulfilling the 
inclusion criteria. Patients diagnosed on history, 
clinical examination, CT scan and MRI brain. They 
were asked to sign informed consent for the surgical 
procedure and using their data in research. All patients 
were operated by the same surgical team and muscular 
rigidity was measured pre- and post-operatively by 
using Unified Parkinson Disease Rating Score part 22. 
 Along CT and MRI brain other baseline 
investigations like CBC, LFTs, RFTs, blood sugar 
level, X-ray chest and ECG were also done for 
surgery’s purpose. 
 
Data Analysis 
Data was analyzed by using SPSS version 21.0
statistical package. Continuous data (age, UPRDS 
grade) were presented as mean and standard deviation. 
While, categorical variables (gender and 
improvement) were presented as frequency and 
percentage. Data was stratified for age, gender, 
duration of PD, baseline UPRDS grade and duration of 
medical treatment to deal effect modifiers. Post-
stratification, the chi - square test was applied. p-value 
≤ 0.05 was considered as significant. 
 
Follow-up 
Patients were asked to remove stitches on 7 post-
operative days. Patients were called for follow up after 
3 weeks and then after 3 months to assess reduction in 
muscular rigidity by using UPDRS part 22 and hence 
assess the frequency of effectiveness of Pallidotomy. 
 
RESULTS 
The patients included in this study were of 30 years to 
65 years. The mean age of patients was 54.32 ± 7.23 
years presented in Table 1. According to results, the 
 
Table 1:  Mean age of the patients. 
 
Age of patient (years) 
N 75 
Mean 54.32 
SD 7.23 
Minimum 30 
Maximum 65 
 
prevalence was more common in male patients (n = 
55, 73.3%) as compared to females (n = 20, 26.7%). 
Male to female ratio was 2.75:1. The mean duration of 
diagnosis of Parkinson’s disease was 6.52 ± 2.62 years 
illustrated in Table 2. The minimum duration was 1 
year, while maximum duration was noted 15 years. 
The mean duration of treatment was 5.05 ± 2.07 years. 
 
Table 2:  Duration of disease. 
 
Duration(years) 
N 75 
Mean 6.52 
SD 2.62 
Minimum 1 
Maximum 15 
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The minimum duration of disease was 1 year, while 
maximum duration was 9 years. At the time of 
presentation, the baseline UPDRS score for rigidity 
was 3 in 37 (49.3%) patients while 4 in 38 (50.67%) 
patients (Table 3). In our study, all (100%) patients 
 
Table 3:  Distribution of UPDRS grade at baseline. 
 
Grade Number Percentage 
3 37 49.33 
4 38 50.87 
 
showed reduced rigidity with Pallidotomy after three 
months of follow-up (Table 4). At3 months follow-up 
 
Table 4:  Reduction in rigidity. 
 
Improvement in 
rigidity 
 Frequency Percentage 
Yes 75 100% 
No   0      0% 
Total 75 100% 
 
Table 5: Comparison baseline rigidity grades with 
follow-up grades. 
 
 
Follow-up UPDRS 
Rigidity Grade Total 
  1   2 3 4 
Baseline 
UPDRS 
rigidity 
grade 
1   0   0 0 0   0 
2   0   0 0 0   0 
3 32   5 0 0 37 
4 17 21 0 0 38 
Total 49 26 0 0 75 
 
49 (65.3%) patients had UPRDS grade 1 while 26 
(34.7%) had UPRDSS grade 2 and no patient shown 
rigidity of UPRDS grade 3 or 4 (Table 5). Out of 37 
patients who had UPRDS grade 3 at baseline, 32 had 
grade 1 while 5 had grade 2 after Pallidotomy and out 
of 38 patients who had UPRDS grade 4 at baseline, 17 
had UPRDS grade 1 while 21 had UPRDS grade 2 
after Pallidotomy. The difference was calculated to be 
significantly high (p < 0.001). Improvement in 
reduction of rigidity was noted in all patients 
regardless of age and gender and duration shown in 
Table 6. 46 patients were treated for ≤ 5 years and 29 
patients for > 5 years, all shown improvement in 
reduction of rigidity at follow up. 
 
Table 6: Comparison of improvement with baseline 
UPRDS rigidity grade. 
 
 
Improvement 
Total 
Yes No 
Baseline UPDRS 
rigidity grade 
1   0 0   0 
2   0 0   0 
3 37 0 37 
4 38 0 38 
Total 75 0 75 
 
DISCUSSION 
Parkinson’s disease is a degenerative and progressive 
disease of dopamine producing neurons. It is 
characterized by bradykinesia, tremors, muscular 
rigidity and postural instability. It was treated 
surgically in initial period, but at the high rate of 
complications.
8
 In 1960, Levodopa was introduced 
which remarkably reduced symptoms of Parkinson’s 
disease.
9
 It was noted that after a certain period of time 
levodopa causes abnormal movements of the body 
known as dyskinesia. These dyskinetic movements 
were very cumbersome for patients and for caretaker 
as well. With the passage of time, frequency and 
severity of dyskinetic movements increases, which led 
the patients either to wheelchair bound or bed bound. 
To coup this adverse effects pallidotomy was 
reintroduced with more accuracy and precision and 
with advanced neuromonitoring and imaging.
10
 
 Pallidotomy is a technically demanding procedure, 
but its results are good.  Its treatment goals are to 
prevent dyskinesia, reduced rigidity of muscles and 
improve quality of life of the patients. Parkinson’s 
disease is slow and progressive degenerative disorder. 
It takes years to develop motor symptoms, though the 
process of degeneration started years back. As shows 
in this study that 18 patients (n = 75, 24.0%) have the 
disease for 5 years, 16 patients (21.3%) for 6 years, 9 
patients (12.0%) for 7 and 8 years each, 4 patients 
(5.3%) for 9 years, 7 patients (9.3%) for 10 years and 
3 patients (3.9%) have for 1, 12 and 15 years each. 
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Clinical manifestations appeared when more than 50% 
dopaminergic neuronal loss occurred.
12
 The 
Parkinson’s disease progresses in stages. In the Braak 
staging system
13
 stage 1 is pre-symptomatic stage, in 
this stage cell loss has occurred but not in insignificant 
number to cause symptoms. In stage 2, a cell loss 
occurred in olfactory bulb resulted in a decreased 
sense of smell along with neural loss in enteric plexus 
resulted in constipation and sleep disorders. In stage 3 
motor symptoms like rigidity and tremors appeared 
and took many years to develop. It is associated with 
50% neuronal loss in the substantia nigra. In stage 4, 
neuronal loss reached up to mesocortex and in stage 5 
and 6 this loss reached to cortical areas which are 
responsible to control cognition and emotions of the 
patients resulted in confusion and dementia. 
 Parkinson’s disease is a disease of different age 
groups, but usually occurred in middle to old age 
groups. Stephen et al (2011), studied the incidence of 
Parkinson’s disease which rises with age14 and rapidly 
increased after the age of 60. Its onset before 40 years 
is rare. It was seen in the study that only 1 patient 
(1.3%) was presented at the age of 30 while 2 patients 
(2.7%) presented at the age of 40. The difference in 
onset of disease could be due to environmental, host 
response or genetics and hereditary.
15
 As the study 
shows that the maximum incidence lies between fifth 
and sixth decades. Seven patients (9.3%) were 
presented in 65 years of age. Mean age of presentation 
was 54.30 years shown in Table 1. 
 Regarding the incidence of PD, it was more 
common in male than female. Wooten (2004)
16
 
described that Parkinson disease seems to occur more 
commonly in men than woman. He concluded his 
hypothesis on the basis of an increased death rate and 
prevalence of Parkinson’s disease in men. The risk of 
developing Parkinson’s disease is 1.5 in men as 
compared to women. The reason for this increase 
number of men’s involvement is that men are more 
prone to trauma, exposure to environmental toxicant, 
neuroprotection of women by sex hormone like 
estrogen, mitochondrial dysfunction, genetics risk 
factors related to X linkage.
17
 Estrogen works as 
neuroprotective in nature. It activates the mitogen 
activated protein kinase pathways and it also helps in 
free radicals scavenging by glutathione.
18
 
 Anthony et al 2007, hypothesized that when the 
disease reached up to substantia nigra other processes 
triggered like oxidative stress, resulted in increased 
turnover of dopamine, reduced level of glutathione, 
increased iron and excitotoxicity. Specific disease 
modifying therapies should require which address not 
only the basic mechanisms of the neurodegeneration 
and the additional biologic processes specific to the 
dopamine producing structure like subthalamic 
nucleus.
19
 
 Patients suffering from Parkinson disease require 
long term treatment which resulted in abnormal drug 
induced movements. This study shows 4 patients (n = 
75, 5.3%) required treatment for 1 year, 5 patients (n = 
75, 6.7%) for 2 years, 6 patients (n=75, 8%) for 3 
years, 15 patients (20%) for 4 years, 16 patients 
(21.3%) for 5 years, 12 patients (16%) for 6 years, 6 
patients (8%) for 7 and 8 years each and 5 patients 
(6.5%) for 9 years. Annete et al (2000),
20
 estimated 
that 10% of patients taking Antiparkinson medicines 
developed motor fluctuation per year
21
 and 50% of 
these patients suffered drug induced complications 
after 5 years.
22
 Motor complication prone to occur in 
younger onset of disease and with greater disease 
severity.
23
 
 The current study included different stages of 
Parkinson’s disease and different UPDRS score. 37 
patients (n = 75, 49.3%) presented with the UPDRS 
rigidity score 3 and 38 patients (50.9%) with rigidity 
score 4. After Pallidotomy assessment of patients were 
done by UPDRS rigidity score on first post-operative 
day and after three months. There was marked 
reduction in rigidity subjectively and objectively. The 
mean UPDRS score for rigidity at admission was 
3.507 and on follow-up after three months mean 
UPDRS score for rigidity was 1.346. There was 
improvement in UPDRS score in term of reduction in 
rigidity was 2.161 (chi-square test 14.427, p = 0.0001). 
M. Dalai et al (1995) published his experience of 18 
patients with Parkinson, refractory to medical therapy 
and developed drug induced dyskinesia. He found that 
following Pallidotomy, patients improved in their 
symptoms like rigidity, bradykinesia, tremors with 
resolution of drug induced dyskinesia. He compared 
pre-operative and post-operative UPDRS score and 
found significant improvement (65%) in rigidity 
score.
24
 
 
CONCLUSION 
This study infers Pallidotomy for Parkinsonian 
muscular rigidity developed drug induced dyskinesia 
is better surgical procedure which keep improving in 
reduction with time. It is associated with less number 
of complications, more effective than previous and 
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especially in improving the quality of life of 
Parkinsonian patients. 
 
ROLE OF AUTHORS 
Dr. Imran Ali: Paper Writing. 
Dr. Hassaan Zahid: Results Writing. 
Dr. Adeeb-ul-Hassan: Paper Editing and Results 
Writing. 
Dr. Khalid Mahmood: Study Design. 
 
Additional Information 
Disclosures and Conflict of Interests: 
Authors report no conflict of interest. 
Human Subjects: Consent was obtained by all 
patients/participants in this study. 
In compliance with the ICMJE uniform disclosure form, all 
authors declare the following: 
Financial Relationships: All authors have declared that 
they have no financial relationships at present with any 
organizations that might have an interest in the submitted 
work. 
Other Relationships: All authors have declared that there 
are no other relationships or activities that could appear to 
have influenced the submitted work. 
 
Address for Correspondence: 
Dr. Imran Ali, Punjab Institute of Neuro-Sciences 
(PINS), Lahore General Hospital, Lahore 
Email: imsiddiqui1979@yahoo.com 
 
REFERENCES 
1. Damier P, Hirsch EC, Agid Y, Graybiel M.  Brain.The 
substantia nigra of the human brain: II. Patterns of loss 
of dopamine-containing neurons in Parkinson's disease, 
1999, 122 (8): 1437-1448. 
2. Ma Y, Stebbins G, Jaffar S, Dopamine transporter 
immunoreactive neurons decrease with age in human 
substrantia nigra, Journal of comparative Neurology, 
1999; 409 (1). 
3. Koller W, Gray C, Alexander C, Environmental risk 
factors in Parkinson’s disease, 1990; 40 (8). 
4. Stephen K, Carolin M, Allan L, incidence of 
Parkinson’s disease: Variation by age, Gender and 
Race/Ethnicity, American Journal of Epidmiology, 
2003; 157 (11): 1015-1022. 
5. Dr Panel K, Scab D, Healy G, Non-motor symptoms of 
Parkinson’s Disease: diagnosis and management, The 
Lancet Neurology, 2006;5 (3): 235-245. 
6. Caroline M, The Role of environmental toxins in 
etiology of Parkinson’s Disease, Trends in 
Neuroscience, 1989; 12 (2): 49-54. 
7. Alberto A, Holangi C, Mark G,Pesticide exposure and 
risk for Parkinson’s disease, Annual of Neurology, 
2006;60 (2). 
8. Yoshinori H, Robert I,Surgical implications in patients 
with Parkinson’s disease after Posteroventral 
Pallidotomy, Neurosurgery, 2003; 52 (3): 558-571. 
9. Warren C, Yoshi Mizuno, Bonucelli U, Levodopa in 
the treatment of Parkinson’s disease: current 
controversies, Movement disorders, 2004; 19. 
10. Lauri V, Laitinen A, Marwan I,Leksell’sPosteroventral 
pallidotomy in the treatment of Parkinson’s disease, 
journal of Neurosurgery (JNS), 1992;76 (1). 
11. Iacono RP, Shima F, Lonser RR, Maeda G, The results, 
indications and physiology of Posteroventral 
pallidotomy for patients with Parkinson’s disease, 
Neurosurgery, 1988, 36 (6): 1118-1125. 
12. Etienne Hirsch, Ann M, Yves A. Melanized 
dopaminergic neurons are differently susceptible to 
degenrationin Parkinson’s disease, Nature, 1988; 334: 
345-348. 
13. Robert E, William T, Paul G. A critical evaluation of 
the Braak staging scheme for Parkinson’s disease, 
Annals, of Neurology, 2008; 64 (5). 
14. Stephen K, Caroline M, Allan L, Robin D. Incidence of 
Parkinson’s disease: Variation by age, Gender and 
Race/ethinicity, American Journal of Epidemiology, 
2003; 157 (11): 1015-1022. 
15. Mayeux R, Marder K, Jean Denaro, The frequency of 
idiopathetic Parkinson’s disease by Age, ethenic group 
and sex in northern Manhattan, Am J epidemiol. 1995; 
142: 820-827. 
16. Stephen K, Caroline M, Allan L, Robin D, Incidence of 
Parkinson’s disease: Variation by age, Gender and 
Race/ethinicity, American Journal of Epidemiology, 
2003; 157 (11): 1015-1022. 
17. Tanner C, Goldman M, Ruth Ottman, Epidemiology of 
Parkinson’s disease, Neurol Clin. 1996; 14: 317-335. 
18. Green P, Gridly K, Simplins, Neuclear estrogen 
receptor-independence neuro protection by estratrienes-
a noval interaction with glutathione, Neuroscience, 
1998; 83: 7-10. 
19. Anthony E, The progression of Parkinson’s disease, a 
hypothesis,Neurology, 2007; 68 (12): 948-952. 
20. Anette Scharag, Nial Quinin Brain, Dyskinesia and 
motor fluctuations in Parkinson’s disease, a community 
based study, Brain A journal of neurology, 2000; 123 
(11): 2297-2305. 
21. Marcedes CD, Parkes JD. Success and problems of long 
term levodopa therapy in Parkinson’s disease, 1977; 
309 (8007): 345-349. 
22. Richard D, MCDowell FH. Five years treatment of 
Parkinson’s Disease with Levodopa, therapeutic results 
and survival of 100 patients, Ann Intern Med. 1975; 83 
(4): 456-463. 
23. Ronald P, Stanley Fahn, Stuart R, Lucien J. Analysis of 
clinical problems in Parkinsonism and complications of 
Imran Ali, et al 
-79-         Pak. J. of Neurol. Surg. – Vol. 23, No. 2, Apr. – Jun., 2019         http//www.pakjns.org 
long term levodopa therapy, Analysis of Neurology, 
1979; 29 (9): 1253-1260. 
24. Dogali M, Fazzani E, Kolodny E, Stereotactic ventral 
pallidotomy for Parkinson’s disease, Neurology, 1995; 
45 (4): 753-761. 
 
 
 
Date of Submission: 30-4-2019 
Date of Revision: 09-05-2019 
Date of Online Publishing: 01-06-2019 
Date of Print: 15-6-2019 
 
